Loading quotes...
Forecast
The analysts' average price target is âŹ6.45 (+18.57%). The median is âŹ5.81 (+6.80%).
| Buy |
Â
3 |
| Hold |
Â
7 |
| Sell |
Â
2 |
News Go to news feed
RxSight unveils turnaround plan and strengthens partnership with Alcon
At the Wells Fargo Healthcare Conference, new CEO Aziz Mottiwala presented a strategic realignment plan to intensify use of the lightâadjustable lens (LAL) among existing surgeons and to double U.S. sales through internal reallocations. The partnership closed in July with Alcon includes a $200 million upfront payment and a 30% royalty on future sales, plus access to Alconâs sales network. RxSight has about $210 million in cash (excluding the full Alcon payment), high gross margins, and is working on a nextâgeneration LAL; the company is targeting a return to growth in 2027 but has not provided concrete forecasts. » More on de.investing.com
RxSight appoints Aziz Mottiwala as president and CEO
RxSight appointed Aziz Mottiwala, effective July 20, as president and chief executive officer; he replaces Dr. Ron Kurtz, who will move to chief medical officer and leave the board of directors, while Mottiwala will be named to the board. Mottiwala joins from Tarsus Pharmaceuticals and brings experience in senior sales and commercial roles in ophthalmology. The stock is under pressure (about â8% last week, â50% over six months) and is trading at $5.25 (market capitalization $216.92 million). The company manufactures the Light Adjustable Lens System and said it would not change its prior financial guidance. » More on de.investing.com
RxSight cuts 2026 revenue forecast after competitive pressure
RxSight lowered its 2026 revenue forecast to $110â120 million (previously $120â135 million), triggering a roughly 12.9% share price decline. The total revenue outlook of $140â160 million includes $30â40 million from the Alcon collaboration; preliminary Q2 revenues are expected at $32â34 million ( $5â7 million from the Alcon partnership, about $27 million from product sales). The company cited "significant commercial headwinds" and plans to accelerate sales investments while maintaining spending discipline; gross margin guidance was raised to 73â75%, and operating expenses remain at the high end of the $150â160 million range. Cash and equivalents totaled about $209 million as of June 30; RxSight is working on a next generation of Light Adjustable Lens products. » More on de.investing.com
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 29.56M | 3.59% |
| Gross profit | 22.68M | 6.13% |
| Net profit | -10.6M | 6.00% |
| EBITDA | -9.64M | 3.68% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | âŹ226.96M |
Number of shares | 41.4M |
52-week high/low | âŹ11.37 - âŹ3.85 |
| Dividends | No |
Beta | 1.16 |
P/E ratio | -5.64 |
PEG ratio | 0.17 |
P/B ratio | 1.00 |
P/S ratio | 2.07 |
Company profile
RxSight, Inc. ist ein Medizintechnikunternehmen, das sich mit der Erforschung und Entwicklung, der Herstellung und dem Verkauf von lichtverstellbaren Intraokularlinsen (LAL) beschĂ€ftigt, die in der Kataraktchirurgie in den Vereinigten Staaten und international eingesetzt werden. Das Unternehmen bietet das RxSight-System an, das es Ărzten ermöglicht, die SehschĂ€rfe von Patienten nach einer Kataraktoperation individuell anzupassen und zu verbessern. Das RxSight-System des Unternehmens umfasst das RxSight-LichtabgabegerĂ€t, ein LichtbehandlungsgerĂ€t fĂŒr die Praxis, das UV-Licht in einem programmierten Muster abgibt, um die LAL auf der Grundlage der Sehkorrektur zu modifizieren, die erforderlich ist, um das gewĂŒnschte Sehvermögen nach einer Kataraktoperation zu erreichen. Das Unternehmen beliefert in erster Linie Katarakt-Ărzte. Das Unternehmen war frĂŒher als Calhoun Vision, Inc. bekannt und Ă€nderte im Februar 2017 seinen Namen in RxSight, Inc. RxSight, Inc. wurde 1997 gegrĂŒndet und hat seinen Hauptsitz in Aliso Viejo, Kalifornien.
| Name | RXSIGHT INC. DL -,001 |
| CEO | Aziz Mottiwala |
| Headquarters | Aliso Viejo,
ca USA |
| Website | |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| IPO | 07/30/2021 |
| Employees | 461 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | RXST |